



**Figure S1. The mRNA expression of IL-10 and TGF- $\beta$  is not associated with overall survival.** (A and B) Kaplan–Meier curves of overall survival according to the mRNA expression of IL-10 (A) and TGF- $\beta$  (B) in dogs with prostate cancer ( $n = 18$ ). Cases were classified as having a high or low mRNA expression according to the median number ( $n = 9$  each). Log-rank test.




**Figure S2. Urinary and serum CCL22 concentration in dogs with prostate cancer.**


(A) Urinary CCL22 concentration in normal dogs ( $n = 14$ ) and in dogs with prostate cancer ( $n = 19$ ). Mean values are depicted by horizontal lines. NS, not significant, nonparametric Mann–Whitney  $U$  test. (B) Serum CCL22 concentration in normal dogs ( $n = 10$ ) and in dogs with prostate cancer ( $n = 19$ ). NS, not significant, nonparametric Mann–Whitney  $U$  test.




**Figure S3. BRAF<sup>V595E</sup> mutation is associated with intratumoral Foxp3<sup>+</sup> Tregs, CCR4<sup>+</sup> cells, and urinary CCL17 concentration in dogs with prostate cancer. (A–C)** The number of intratumoral Foxp3<sup>+</sup> Tregs (A), CCR4<sup>+</sup> cells (B), and urinary CCL17 concentrations (C) in canine prostate cancer cases with wild-type BRAF and BRAF<sup>V595E</sup> mutation. \* $P < 0.05$ , nonparametric Mann–Whitney  $U$  test.



**Figure S4. BRAF gene alterations in human prostate cancer.** Histogram displaying frequency of BRAF gene somatic mutation, fusion, copy-number amplification, deletion, and multiple alterations across eight human prostate cancer genomic datasets.



**Figure S5. Intratumoral Foxp3<sup>+</sup> and CCR4<sup>+</sup> cells in two dogs with prostate cancer before and after mogamulizumab treatment.** Before treatment, a number of Foxp3<sup>+</sup> and CCR4<sup>+</sup> cells were observed in the tumor tissue. After three (Case M2) and 33 cycles (Case M3) of mogamulizumab treatment, both Foxp3<sup>+</sup> and CCR4<sup>+</sup> cells were clearly decreased when compared with the pre-treatment tissue.



**Figure S6. Cross-species t-SNE analysis of canine and human prostate tissues.** Differentially expressed genes ( $q < 0.01$ ) between canine prostate cancer and normal prostate were selected and extracted concordant genes in the expression data of humans. The expression patterns of 2,297 differentially expressed genes in the cross-species tissues were visualized with t-SNE. Color-coded sphere showed each type of prostate tissue as following; red: canine normal prostate, green: canine prostate cancer, blue: human normal prostate, purple: human prostate cancer.